Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Chalas

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Obstetrics and Gynecology|August 2, 2002
A randomized controlled trial of a regular diet as the first meal in gynecologic oncology patients undergoing intraabdominal surgeryMichael L Pearl, Martina Frandina, Linda Mahler, et al.
Gynecologic and Obstetric Investigation|July 1, 2006
Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapyPaul A DiSilvestro, Margaret Fisher, Michael L Pearl, et al.
Journal of Minimally Invasive Gynecology|April 22, 2018
Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation"William H Parker, Jonathan S Berek, Elizabeth A Pritts, et al.
Journal of Minimally Invasive Gynecology|August 23, 2017
Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation"William H Parker, Jonathan S Berek, Elizabeth A Pritts, et al.
Gynecologic Oncology|September 10, 2002
Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancerJeannine A Villella, Taimur Chaudhry, Michael L Pearl, et al.
American Journal of Obstetrics and Gynecology|April 23, 2005
Benign gynecologic conditions among participants in the Breast Cancer Prevention TrialEva Chalas, Joseph P Costantino, D Lawrence Wickerham, et al.
International Journal of Oncology|September 12, 2006
Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancersKerstin Becker, Petr Pancoska, Nicole Concin, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 7, 2007
Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis?Nicole R Howell, Wenxin Zheng, Liang Cheng, et al.
Obstetrics and Gynecology|August 25, 2010
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancerJonathan S Berek, Eva Chalas, Mitchell Edelson, et al.
The Journal of Experimental Medicine|September 18, 2002
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumorsAlex I Zaika, Neda Slade, Susan H Erster, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Obstetrics and Gynecology|August 2, 2002
A randomized controlled trial of a regular diet as the first meal in gynecologic oncology patients undergoing intraabdominal surgeryMichael L Pearl, Martina Frandina, Linda Mahler, et al.
Gynecologic and Obstetric Investigation|July 1, 2006
Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapyPaul A DiSilvestro, Margaret Fisher, Michael L Pearl, et al.
Journal of Minimally Invasive Gynecology|April 22, 2018
Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation"William H Parker, Jonathan S Berek, Elizabeth A Pritts, et al.
Journal of Minimally Invasive Gynecology|August 23, 2017
Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation"William H Parker, Jonathan S Berek, Elizabeth A Pritts, et al.
Gynecologic Oncology|September 10, 2002
Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancerJeannine A Villella, Taimur Chaudhry, Michael L Pearl, et al.
American Journal of Obstetrics and Gynecology|April 23, 2005
Benign gynecologic conditions among participants in the Breast Cancer Prevention TrialEva Chalas, Joseph P Costantino, D Lawrence Wickerham, et al.
International Journal of Oncology|September 12, 2006
Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancersKerstin Becker, Petr Pancoska, Nicole Concin, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 7, 2007
Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis?Nicole R Howell, Wenxin Zheng, Liang Cheng, et al.
Obstetrics and Gynecology|August 25, 2010
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancerJonathan S Berek, Eva Chalas, Mitchell Edelson, et al.
The Journal of Experimental Medicine|September 18, 2002
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumorsAlex I Zaika, Neda Slade, Susan H Erster, et al.
Pageof 4